You have had plaque psoriasis for years. A wellness newsletter lands in your inbox promising that an “NAD booster” calms skin inflammation, with a chart of immune cells and a link to a research catalog. You wonder whether any human trial actually tested that claim in people with psoriasis–or whether the ad is borrowing biology from somewhere else.
One randomized, placebo-controlled study did test oral nicotinamide riboside in mild-to-moderate psoriasis. It measured immune signals in blood and skin-related pathways. It did not prove that plaques clear, and it did not test a research-catalog vial.
What the JCI Insight psoriasis trial recorded
Han and colleagues reported the work in JCI Insight in 2026. Adults with mild-to-moderate psoriasis took oral nicotinamide riboside or matching placebo for four weeks. Blood was drawn before and after. The trial registration listed on the paper includes NCT04271735.
Nicotinamide riboside reduced Th17 immune responsiveness. RNA sequencing of CD4 T cells pointed to SLIT-ROBO signaling. Circulating SLIT2 rose, and dermal fibroblasts made more SLIT2. Lab follow-up suggested SLIT2 acting through the ROBO1 receptor dampened the usual Th17 polarization path and fibroblast inflammatory activation. In plain terms: the NAD precursor shifted a fibroblast-T-cell conversation that feeds psoriasis inflammation.
The paper is mechanism-forward. It does not advertise itself as a new first-line psoriasis drug trial with PASI clearance as the headline win. That distinction matters when an ad uses the same molecule name.
How this sits next to other NAD stories
Everyday Brief has covered NAD precursor blood markers, IV drip tolerability notes, the NOPARK Parkinson phase 3 miss, a mild cognitive impairment pilot that raised NAD without cognitive gain, and a Friedreich ataxia factorial trial where exercise carried the fitness signal. Psoriasis Th17 biology is a sixth reader situation. None of those files evaluated a catalog listing sold for everyday “skin reset.”
NIAMS and MedlinePlus psoriasis pages still center clinician-guided care: topical regimens, phototherapy, and systemic medicines when needed. An inbox chart is not a care plan.
What to notice before you change anything
Ask whether the claim points to this randomized four-week immune study, to a different NAD precursor trial in another disease, or to a product page. Ask your clinician which psoriasis measures they are watching and whether any NAD precursor study is relevant to your severity and current regimen.
A Th17 dampening signal in a short trial can look decisive in a newsletter. In the published paper it is an immune-pathway finding, not proof that plaques will fade on a catalog schedule.
Not medical advice.
Sources
- Han K et al. NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis. JCI Insight, 2026 (PubMed)
- Full text: Han et al. 2026 nicotinamide riboside psoriasis trial (PubMed Central)
- ClinicalTrials.gov: NCT04271735
- NIAMS: Psoriasis
- MedlinePlus: Psoriasis
Related reading
- Friedreich ataxia, exercise, and an NAD booster factorial trial
- Mild cognitive impairment pilot: NAD rose, cognition did not
- NAD precursors raise markers, not proof of anti-aging
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-15 PT. Not medical advice.